AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Pulmicort (budesonide) — Established RoW YoY CER by Quarter
Pulmicort (budesonide) — Established RoW YoY CER (%) (%)
AstraZeneca Pulmicort (budesonide) — Established RoW YoY CER: -17.0% in Q2 2026, down 19.0 pts from a year earlier.
Latest, Q2 2026
-17.0%
Period ended Jun 30, 2026
Change on a year earlier
-19.0 pts
2.0% in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below
Where the Q2 2026 figure comes from
“|| Pulmicort | 120 | | 13 | | 9 | | 2 | | 11 | | 97 | | 20 | | 15 | | 14 | | ( 5 ) | | ( 9 ) | | 7 | | ( 17 ) | | ( 17 )”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AstraZeneca Pulmicort (budesonide) — Established RoW YoY CER (%), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-pulmicort-erow-cer-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.